BioCryst to Report Third Quarter 2024 Financial Results on November 4

BCRX 10.21.2024

Full Press ReleaseSEC FilingsOur BCRX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
  • 01.07.2025 - BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) --BioCryst Pharmaceuticals, Inc.(Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website atwww.biocryst.com.

About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO®(berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:John Bluth+1 919 859 7910jbluth@biocryst.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com